Rituximab for Patients with Idiopathic Thrombocytopenic Purpura
Authors: Donald M. Arnold, Mark A. Crowther
Journal: Annals of Internal Medicine (2007)

Letters21 August 2007Rituximab for Patients with Idiopathic Thrombocytopenic PurpuraDonald M. Arnold, MD, MSc and Mark A. Crowther, MD, MScDonald M. Arnold, MD, MScFrom McMaster University, Hamilton, Ontario L8N 3Z5, Canada.Search for more papers by this author and Mark A. Crowther, MD, MScFrom McMaster University, Hamilton, Ontario L8N 3Z5, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-4-200708210-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We appreciate the comments from Drs. Peñalver and Cabrera about our systematic review of rituximab in ITP. Our inclusion criteria for primary reports in the review had to be fairly liberal because most reports were case series or cohort studies, reflecting, perhaps surprisingly, the paucity of methodologically rigorous trials in this field. Nevertheless, we established a priori that care must be taken to avoid redundant publications, because many were published in abstract form only and some were follow-up reports of preliminary studies.The report by Peñalver and colleagues gave us reason to pause (1). In fact, the authors ...References1. Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400-6. [PMID: 16550390] CrossrefMedlineGoogle Scholar2. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. [PMID: 10789670] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Donald M. Arnold, MD, MSc; Mark A. Crowther, MD, MScAffiliations: From McMaster University, Hamilton, Ontario L8N 3Z5, Canada.Disclosures: Dr. Arnold has received a grant from Hoffman-LaRoche, Canada, for the conduct of a clinical trial of rituximab in ITP. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura Donald M. Arnold , Francesco Dentali , Mark A. Crowther , Ralph M. Meyer , Richard J. Cook , Christopher Sigouin , Graeme A. Fraser , Wendy Lim , and John G. Kelton Rituximab for Patients with Idiopathic Thrombocytopenic Purpura Francisco Javier Peñalver and Jose Rafael Cabrera Metrics Cited byQuelle prise en charge thérapeutique pour le purpura thrombopénique auto-immun ?Development of Common Variable Immunodeficiency in an 8-year-old Boy Treated with Rituximab for Idiopathic Thrombocytopenia 21 August 2007Volume 147, Issue 4Page: 281-282KeywordsCase seriesClinical trialsCohort studiesConflicts of interestDrug distributionDrug therapyIdiopathic thrombocytopenic purpuraQuestionnairesSafetySystematic reviews ePublished: 21 August 2007 Issue Published: 21 August 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...